# 22nd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy

**October 1-4, 2020**

**Chairs:** J. Cortes, T.P. Hughes, D.S. Krause  
**Co-Organizers:** R. Bhatia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel, F-X. Mahon, D. Perrotti, J. Radich, D. Réa  
**Advisory Committee:** J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot, R. Hehlmann, P. Laneuville, G. Saglio, C. Schiffer, S. Soverini, P. Valenti, R. Van Etten

## Thursday, October 1, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:10</td>
<td>WELCOME</td>
<td>Jorge Cortes (Augusta)</td>
</tr>
<tr>
<td>14:10-14:20</td>
<td>iCMLf - A REVIEW</td>
<td>Tim P. Hughes (Adélaide)</td>
</tr>
<tr>
<td>14:20-14:48</td>
<td>SPECIAL INTRODUCTORY LECTURE</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Jerry Radich (Seattle)</td>
<td></td>
</tr>
<tr>
<td>14:20-14:25</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>14:25-14:38</td>
<td>Title: TBA</td>
<td>John Dick (Toronto)</td>
</tr>
<tr>
<td>14:38-14:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>14:45-16:45</td>
<td>SCIENTIFIC SESSION 1: TOP SCORING ABSTRACTS 2020</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong></td>
<td></td>
</tr>
<tr>
<td>14:48-15:45</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>14:48-15:00</td>
<td>Targeted RNA-Based Gene Sequencing Identifies Mutated Blood Cancer-Linked Genes at Diagnosis of CML That Are Associated with Treatment Failure</td>
<td>Susan Branford (Adelaide)</td>
</tr>
<tr>
<td>15:00-15:15</td>
<td>TgfBr - SMAD3 Signaling Protects CML and Other Myeloid Malignancies from Synthetic Lethality Triggered By PARP Inhibitor in Bone Marrow Microenvironment</td>
<td>Bac Viet Le (Warsaw)</td>
</tr>
<tr>
<td>15:15-15:30</td>
<td>Interim Analysis from the Optic Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib</td>
<td>Jorge Cortes (Augusta)</td>
</tr>
<tr>
<td>15:30-15:45</td>
<td>Deceiving and Drugging BCR-ABL1 Compound Mutants: Pairing a Conformational Influencer with Ascmib or an Ascmib Proteolysis-Targeting Chimera (PROTAC)</td>
<td>Thomas O’Hare (Salt Lake City)</td>
</tr>
</tbody>
</table>
15:39-15:51  Therapeutic Inhibition of Malignant Fcγrllb-Induced BTK Activation Targets Leukemic Stem Cells in Chronic Myeloid Leukemia  Mirle Schemionek (Aachen)

15:51-16:03  Molecular Status 36 Months after TKI-Discontinuation in CML Is Highly Predictive for Later Loss of MMR - a Report from after-SKI.  Johan Richter (Lund)

16:03-16:15  Protein Transfer between CML and Bone Marrow Stromal Cells: Functional Meaning and the Involvement of Tnts  Marta Kolba (Warsaw)

16:15-16:40  Discussion

16:40-16:50  Break

16:50-17:18  TESSA HOLYOAKE MEMORIAL LECTURE: SPECIAL LECTURE Chair:

16:50-16:53  Introduction

16:53-17:08  Understanding and targeting the stem cell origins of myeloid malignancies  Ulrich Steidl (New York)

17:08-17:18  Discussion

17:18-19:05  SCIENTIFIC SESSION 2: STEM CELLS AND THE MICROENVIRONMENT Chair: TBA

17:18-17:21  Introduction

17:21-17:36  Keynote presentation  TBA (TBA)

17:36-17:46  Discussion

Selected Abstracts

17:46-17:58  The Role of the Autophagy Adaptor Protein PLEKHM1 in the Leukaemic Bone Marrow Microenvironment  Christina Karantanou (Frankfurt)

17:58-18:10  Features of BCR-ABL1 Driven Myeloproliferative Disease in a CML Mouse Model Are Dependent on LSC Age and Fitness  Hassan Almasoudi (Glasgow)

18:10-18:22  Murine Hematopoietic and Leukemic Stem/Progenitor Cell Lines As Model Systems for Bcr/Abl Driven Disease  Veronika Sexl (Vienna)

18:22-18:34  Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Drug-Resistant CML Stem/Progenitor Cells  Andrew Wu (Vancouver)

18:34-18:46  The Spliceosome: An Another Regulating System of Gene Expression Deregulated in CP-CML CD34+CD15- Cells  Benjamin Lebecque (Clermont-Ferrand)

18:46-19:05  Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
</table>
| 19:05-19:15  | JANET ROWLEY PRIZE PRESENTATION                                                                 | Presenter: Rob Welner (Birmingham)  
Awardee 2020: Ravi Bhatia (Birmingham) |
| 19:15-19:30  | JANET ROWLEY PRIZE: SPECIAL LECTURE (2)                                                          | Chair: Rob Welner (Birmingham)  
Title to be announced: Ravi Bhatia (Birmingham) |
| 19:30-19:40  | Discussion                                                                                       | Ravi Bhatia (Birmingham) |
| **Friday, October 2, 2020**               |                                                                                                 |         |
| 11:30-12:15  | SCIENTIFIC SESSION 3: IMMUNOLOGY AND INFLAMMATION                                                | Chair: TBA  
**Introduction** |
| 11:30-11:33  | **Selected Abstracts**                                                                            |         |
| 11:33-11:45  | Sterile Inflammation in Normal Hematopoiesis and Leukemia                                        | Pablo Llavona (Frankfurt) |
| 11:45-11:57  | Immunosuppressive Polarization of T Cell Subsets in Spleen and Bone Marrow of Mice with CML-like Disease | Julian Swatler (Warsaw) |
| 11:57-12:15  | **Discussion**                                                                                   |         |
| **12:15-14:00** | Lunch                                                                                           |         |
| 13:00-14:00  | SATELLITE SYMPOSIUM: RECENT HIGHLIGHTS IN CML: WHAT HAVE WE LEARNED IN 2020?                    | Chair: Philippe Rousselot (France)  
Speakers: Mario Tiribelli (Italy), Jorge Cortes (USA)  
*This educational symposium is organized and funded by Incyte Biosciences International Sàrl* |
| 14:00-15:35  | SCIENTIFIC SESSION 4: THE BIOLOGY OF BLAST PHASE                                                | Chair: TBA  
**Introduction** |
| 14:00-14:03  | **Keynote Presentation**                                                                          | TBA (TBA) |
| 14:03-14:18  | **Discussion**                                                                                   |         |
| 14:18-14:28  | **Selected Abstracts**                                                                            |         |
| 14:28-14:40  | RUNX1 Mutations in Blast Phase Chronic Myeloid Leukemia                                          | Shady Adnan-Awad (Helsinki) |
| 14:40-14:52  | H3K36ME3 Loss in Chronic Myeloid Leukemia Patients in Blast Crisis Is Mediated by an Unbalanced SETD2/KDM4A Activity and CAN be Therapeutically Targeted | Manuela Mancini (Bologna) |
14:52-15:04 Releasing the Brakes on Apoptosis: Investigating Combinations of BH3 Mimetics and Nilotinib in Blast Phase CML  Narissa Parry (Glasgow)

15:04-15:16 Discovery of Novel CIP2A Variant (NOCIVA) and its Clinical Association with Myeloid Leukemias  Elonora Mäkelä (Turku)

15:16-15:33 Discussion

15:35 Biology Posters - Mentored Poster Walk 1
Biology Poster Walk Leaders: TBA

15:35 – 16:35 CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)

- Clinical trial design  Donald Berry (Houston)
- New drugs under development  Jorge Cortes (Augusta) and Tim Hughes (Adelaide)
- Understanding and analyzing the new ELN recommendations  Andreas Hochhaus (Jena) and Michael Mauro (New York)

16:35-16:45 Convene in the Main Conference Hall

16:45-18:20 SPECIAL SYMPOSIUM ON ONCOIMMUNOLOGY IN HEMATOLOGIC MALIGNANCIES
Chairs:

- Introductory overview – concepts and challenges  Jeline Kowalenko (Milan)

16:55-17:07 Novel vaccines  David Scheinberg (New York)
17:07-17:19 CAR-T for myeloid malignancies  Saar Gill (Philadelphia)
17:19-17:31 Bi-specific and allogeneic CAR-T  Xianxin Hua (Philadelphia)
17:31-17:43 Checkpoint inhibitors  Justin Kline (Chicago)
17:43-17:55 Bispecific antibodies in leukemia  Roland Walter (Seattle)
17:55-18:20 General Discussion

18:20-18:48 SPECIAL LECTURE (3):
Chair:

18:20-18:23 Introduction
18:23-18:38 CML blast crisis and the microenvironment  Tannishtha Reya (San Diego)
18:38-18:48 Discussion
Saturday, October 3, 2020

08:50-10:50  WORKSHOP FOR NON-CLINICAL SCIENTISTS #1
PROTEOMICS / SECRETOMICS
Chairs: Oliver Hantschel (Marburg) and Vignir Helgason (Glasgow)

08:50-08:55  Introduction
08:55-09:20  Title: TBA
09:20-09:45  MS-proteomics to uncover the complexity and function of the cell secretome
09:45-10:10  Title: TBA
10:10-10:40  Discussion
10:40-10:50  Conclusion

11:00-11:10  JOHN GOLDMAN PRIZE PRESENTATION
Presenter: Hemant Malhotra (Jaipur)
Awardee 2020: Jane Apperley (London)

11:10-11:25  JOHN GOLDMAN PRIZE: SPECIAL LECTURE (4)
Chair: Hemant Malhotra (Jaipur)
Title to be announced
11:25-11:35  Discussion

11:35-12:50  SCIENTIFIC SESSION 5: NEW TREATMENT STRATEGIES
Chair: TBA

11:38-11:53  Keynote Presentation
11:53-12:03  Discussion

Selected Abstracts

12:03-12:15  A Novel Oral Demethylating Agent, or-2100, in Combination with Tyrosine Kinase Inhibitors Overcomes Resistance in Chronic Myeloid Leukemia
Kazuharu Kamachi (Saga)

12:15-12:27  Targeting Integrated Stress Response Combined with Imatinib As a Novel Strategy to Eradicate Imatinib-Resistant CML Cells
Katarzyna Piwoka (Warsaw)
Activity of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) in CML Patients Failing TKI Therapies Including Ponatinib

Radotinib Treatment for Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to or Intolerant of BCR-ABL1 Tyrosine-Kinase Inhibitors: 60-Month Follow-up of a Phase 2 Study

Discussion

SATELLITE SYMPOSIUM:
TRAVELING THROUGH THE UNSOLVED NEEDS IN CML: TOWARDS NEW STRATEGIES
Chair: Andreas Hochhaus (Jena)
Speakers: Valentin Garcia-Gutiérrez (Madrid), Massimo Breccia (Roma), Delphine Réa (Paris)

This educational symposium is organized and funded by Novartis Oncology

Convene in the Main Conference Hall

ESH INTERNATIONAL JOHN GOLDMAN RESEARCH AWARD CEREMONY
Presenter:

Awardee 2020: Vaidehi Krishnan (Singapore)
High dimensional single-cell analysis to predict TFR at the time of CML diagnosis

SCIENTIFIC SESSION 6: TREATMENT-FREE REMISSION
Chair: TBA

Introduction

Keynote Presentation TBA

Discussion

Selected Abstracts

The rate of BCR-ABL1 decline after TKI commencement is a strong predictor of sustained Treatment Free Remission Naranie Shanmuganathan (Adelaide)

High Level of Successful TKI Discontinuation Outside Clinical Trials - a Population-Based Study from the Swedish CML Registry Johan Richter (Lund)

Efficacy and Safety of Pioglitazone in a Phase II Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia Patients Katia Pagnano (Campinas)

Update of the French Spirit Trial with a Detailed Focus on Treatment Free Remission François Guilhot (Poitiers)
16:36-16:55 Discussion

16:55-17:05 Break

17:05-18:40 Scientific Session 7: Treatment-Free Remission - Predictive Factors

Chair: TBA

17:05-17:08 Introduction

17:08-17:23 Keynote Presentation TBA (TBA)

17:23-17:33 Discussion

Selected Abstracts

17:33-17:45 BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Early Predictive Surrogate for Treatment-Free Remission Failure after Imatinib Discontinuation

Dennis Kim (Toronto)

17:45-17:57 Chronic Myeloid Leukemia Patients’ Concerns during Phase I of the Treatment-Free Remission Journey: Considerations Between Patients and Doctors in the Different CML Advocates Network Regions

Giora Sharf (Netanya)

17:57-18:09 Best Duration of Deep Molecular Remission to Achieve Therapy-Free Remission in Chronic Myeloid Leukaemia

Robert Gale (London)

18:09-18:21 Risk Factor Analysis for Treatment-Free Remission Failure after Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia in Chronic Phase: The Optimal Duration of Total Imatinib Treatment and MR4 Response

Dennis Kim (Toronto)

18:21-18:33 Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study

Frédéric Millot (Poitiers)

18:33-18:50 Discussion

18:50-19:20 Special Lecture (5):

Chair:

18:50-18:53 Introduction

18:53-19:08 Human evolutionary genomic medicine

Melissa Ilardo (Salt Lake City)

19:08-19:18 Discussion
14:30-16:30  WORKSHOP FOR NON-CLINICAL SCIENTISTS #2
ARTIFICIAL INTELLIGENCE / MACHINE LEARNING
Chairs: Michael Deininger (Salt Lake City) and Daniela Krause (Frankfurt)

14:30-14:35  Introduction
14:35-15:00  Long-term single-cell quantification:
new tools for old questions
Timm Schroeder (Basel)

15:00-15:25  Computational Pathology: Towards Precision Medicine
Andrew Janowczyk (Cleveland)

15:25-15:50  TBA

15:50-16:20  Discussion

16:20-16:30  Conclusion

15:30-16:30  Clinical Posters - Mentored Poster Walk 2
Clinical Poster Walk Leaders: TBA

16:30-16:58  SPECIAL LECTURE (6):
Chair: TBA

16:30-16:33  Introduction

16:33-16:48  Single cell RNA sequencing in MPN
Bethan Psaila (Oxford)

16:48-16:58  Discussion

17:00-18:18  DEBATE: “SWITCH TO A MORE POTENT DRUG TO GAIN ELIGIBILITY FOR TFR?”
Chair:

17:00-17:03  Introduction

17:03-17:08  Voting

17:08-17:28  Against: Charles Schiffer (Detroit)

17:28-17:48  For: Giuseppe Saglio (Turin)

17:48-18:18  Voting and Discussion

18:20-18:30  iCMLf PRIZE PRESENTATION:
Presenter: Jerry Radich (Seattle)
Awardee 2020: Sabira Kurtovic (Sarajevo)

18:30-18:45  iCMLf PRIZE: SPECIAL LECTURE (7)
Chair: Jerry Radich (Seattle)

CML management in war and peace: lessons that shaped future approaches
Sabira Kurtovic (Sarajevo)
18:45-18:55 Discussion

18:55-17:40 SCIENTIFIC SESSION 8: TKI SAFETY
Chair: TBA

18:55-18:58 Introduction

18:58-19:13 Keynote presentation
Novel trial designs
Donald Berry (Houston)

19:13-19:23 Discussion

Selected Abstracts

19:23-19:35 Cellular Metabolic Flexibility to Explain Interindividual Susceptibility for Tyrosine Kinase Inhibitor-Induced Muscle Complaints
Lando Janssen (Nijmegen)

19:35-19:47 Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib Phase 2 PACE Trial (NCT01207440) in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia
James Januzzi (Boston)

19:47-19:59 High Body Mass Index (BMI) and Treatment Responses in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Receiving First-Line Dasatinib or Imatinib: Exploratory Post Hoc Analysis of the Phase 3 DASISION Study
Massimo Breccia (Rome)

19:59-20:11 Discussion

20:15 Meeting Adjourned